Skip to content

Effects of Motor Imagery and Action Observation in People With Multiple Sclerosis

Investigation of the Effects of Motor Imagery and Action Observation in People With Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05377476
Enrollment
48
Registered
2022-05-17
Start date
2022-06-01
Completion date
2024-06-01
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Motor Imagery, Action Observation, Walking, Fatigue, Trunk Control

Brief summary

It was planned to examine the effects of motor imagery and action observation applied in addition to standard rehabilitation in people with multiple sclerosis on walking, fatigue, and trunk control.

Interventions

Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.

Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.

OTHERstandard rehabilitation

40 minutes of standard rehabilitation.

Sponsors

Bandırma Onyedi Eylül University
CollaboratorOTHER
Hacettepe University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Being between the ages of 18-65 * A definitive diagnosis of MS by a neurologist according to the 2017 McDonald Criteria * Expanded Disability Status Scale (EDSS) score of 4.0 and below (it is determined routinely by the physician during the examination) * Not having an attack in the last 3 months * A minimum score of 4 in each motor imagery ability (internal visual imagery, external visual imagery, and kinesthetic imagery) on the Movement Imagery Questionnaire-3 (MIQ-3)

Exclusion criteria

* cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score of less than 24 * Having another musculoskeletal, cardiovascular, pulmonary, metabolic, or neurological disease severe enough to preclude participation in the study. * Having severe vision and hearing problems

Design outcomes

Primary

MeasureTime frameDescription
6 Min Walking Test6 weekIt will be used to measure walking distance. Before the test is administered, individuals will be given the necessary information and will be asked to walk as fast as possible on a 30-meter track for 6 minutes.

Secondary

MeasureTime frameDescription
Timed Up and Go Test6 weekIt will be used to evaluate the dynamic balance of individuals while walking. Individuals will be asked to stand up from the chair they are sitting on without support and walk a distance of 3 meters, then return from the designated area and sit on the chair without support.
Multiple Sclerosis Walking Scale-126 weekIt is a scale used to measure perceived walking ability. The lowest possible total score on the scale is 12, while the highest is 60. An increase in the total score indicates a negative impact on walking ability.
RehaGait® (Hasomed, Magdeburg, Germany) Gait Analysis6 weekThe device gives about the time-distance characteristics and kinematic data of the gait.
Fatigue Severity Scale6 weekIt is a scale that evaluates the extent to which fatigue affects the daily functions of MS patients. The lowest score that can be obtained from the scale is 7, while the highest score is 63. It is accepted that the severity of fatigue increases as the total score increases.
Trunk Impairment Scale6 weekTrunk control was assessed using the Trunk Impairment Scale (TIS), which consists of three subscales: static sitting balance, dynamic sitting balance, and coordination. The lowest possible total score on the scale is 0, while the highest is 23. An increase in the total score indicates increased trunk control.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026